Strides Pharma Science Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The Board of Directors has recommended a final dividend of Rs. 5 per equity share, representing a 50% payout for the fiscal year. The company reported a strong annual performance, with consolidated revenue reaching Rs. 48,586.83 million and a consolidated net profit of Rs. 5,745.20 million for the year.
Financial Performance Overview
For the financial year ended March 31, 2026, Strides Pharma Science Limited achieved consolidated revenue of Rs. 48,586.83 million, compared to Rs. 45,653.35 million in the previous year. The consolidated net profit for the period stood at Rs. 5,745.20 million, demonstrating the company’s operational resilience and growth throughout the fiscal year.
Dividend Recommendation
In addition to the financial results, the Board of Directors has recommended a final dividend of Rs. 5 per equity share, having a face value of Rs. 10 each. This dividend, which is subject to approval by shareholders at the upcoming Annual General Meeting, reflects the company’s commitment to returning value to its investors.
Quarterly Performance
Focusing on the final quarter (Q4: Jan-Mar 2026), the company reported consolidated revenue of Rs. 13,234.70 million. The consolidated profit after tax for this quarter was Rs. 1,292.81 million. These figures provide insight into the company’s performance momentum heading into the new fiscal year.
Operational Developments
The company continues to focus on its core ‘Pharmaceutical’ segment, which encompasses the development, manufacturing, and commercialization of pharmaceutical products. Management noted that their strategic focus remains on maintaining robust accounting practices and ensuring compliance with updated industry regulations, including the latest Labour Codes implemented by the government during the fiscal year.
Source: BSE
